Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-01-05
2010-02-09
Mondesi, Robert B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Reexamination Certificate
active
07658927
ABSTRACT:
The subject invention pertains to methods and compositions for protecting feline animals from infection by FIV using immunogens derived from primate immunodeficiency viruses, including HIV and SIV. Methods for vaccinating feline animals with the subject vaccine compositions are described. Feline animals vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with FIV. The subject invention further concerns methods and compositions for protecting humans and other animals against infection by immunodeficiency viruses, such as HIV and FIV.
REFERENCES:
patent: 4861720 (1989-08-01), Pedersen et al.
patent: 5037753 (1991-08-01), Pedersen et al.
patent: 5118602 (1992-06-01), Pedersen et al.
patent: 5275813 (1994-01-01), Yamamoto et al.
patent: 5401628 (1995-03-01), Chiodi
patent: 5510106 (1996-04-01), Yamamoto et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565319 (1996-10-01), Pedersen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5700469 (1997-12-01), McMichael et al.
patent: 5763160 (1998-06-01), Wang
patent: 5846546 (1998-12-01), Hurwitz et al.
patent: 5846825 (1998-12-01), Yamamoto
patent: 5849533 (1998-12-01), Berman et al.
patent: 6107077 (2000-08-01), Yamamoto
patent: 6180370 (2001-01-01), Queen et al.
patent: 6254872 (2001-07-01), Yamamoto
patent: 6407213 (2002-06-01), Carter et al.
patent: 6447993 (2002-09-01), Yamamoto
patent: 6500623 (2002-12-01), Tung
patent: 6503753 (2003-01-01), Rios
patent: 6544528 (2003-04-01), Yamamoto
patent: 2001/0004531 (2001-06-01), Sung et al.
patent: 2002/0032165 (2002-03-01), Johnson et al.
patent: 2002/0156037 (2002-10-01), Volkin et al.
patent: 2003/0104611 (2003-06-01), Johnston et al.
patent: 2003/0223964 (2003-12-01), Barnett et al.
patent: 2004/0009941 (2004-01-01), Johnson et al.
patent: 2004/0047878 (2004-03-01), Deng et al.
patent: 2004/0076632 (2004-04-01), Deng et al.
patent: 2005/0031639 (2005-02-01), Yamamoto
patent: WO 93/01278 (1993-01-01), None
patent: WO 94/20622 (1994-09-01), None
patent: WO 9428929 (1994-12-01), None
patent: WO 96/30045 (1996-10-01), None
patent: WO 02/067984 (2002-09-01), None
Elyar et al., Perspectives on FIV vaccine development, Vaccine, 1997, 15(12/13):1437-1444.
Abimiku, A.G., et al. “HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques,”Nat. Med., 1995, pp. 321-329, vol. 1.
Ackley, C. et al. “Immunologic Abnormalities in Pathogen-Free Cats Experimentally Infected with Feline Immunodeficiency Virus”Journal of Virology, Nov. 1990, pp. 5652-5655, vol. 64, No. 11.
Altschul, S.F. et al. “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,”Nucl. Acids Res., 1997, pp. 3389-3402, vol. 25, No. 17.
Bottiger, B., et al. “Envelope cross-reactivity between human immunodeficiency virus type 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site,”J. Virol., 1990, pp. 3492-3499, vol. 64, No. 7.
Byars, N.E. et al. “Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity”Vaccine, Sep. 1987, pp. 223-228, vol. 5.
Calarota, S.A., et al. “Present status of human HIV vaccine development,” “AIDS”, 2003, pp. S73-S84, vol. 17, Supp. 4.
Cohen, J. “Vaccine results lose significance under scrutiny,”Science, 2003, p. 1495, vol. 299.
De Ronde, A. et al. “Antibody Response in Cats to the Envelope Proteins of Feline Immunodeficiency Virus: Identification of an Immunodominant Neutralization Domain”Virology, 1994, pp. 257-264, vol. 198.
Felgner, P. et al. “Lipofection: A highly efficient, lipid-medicated DNA-transfection procedure”Proc. Natl. Acad. Sci. USA, Nov. 1987, pp. 7413-7417, vol. 84.
Gaucher, D., et al. “Gerbil interleukin-18 and caspase-1: cloning, expression and characterization,”Gene, 2003, pp. 159-166, vol. 307.
Greenberg, A.E., et al. “HIV-2 and natural protection against HIV-1 infection,”Science, 1996, pp. 1959-1960, vol. 272.
Guyader, M., et al. “Genome organization and transactivation of the human immunodeficiency virus type 2,”Nature, 1987, pp. 662-669, vol. 326.
Henderson, D.A., et al. “Smallpox and vaccinia,” In:Vaccines, 3rd Ed., 2004, pp. 123-153, Plotkin SA, Orenstein WA (editors). Elsevier Inc., Philadelphia.
Hosie, M. J. et al. “Protection against Homologous but Not Heterologous Challenge Induced by Inactivated Feline Immunodeficiency Virus Vaccines”Journal of Virology, 1995, vol. 69, No. 2, pp. 1253-1255.
Hosie, M. et al. “Serological responses of cats to feline immunodeficiency virus”AIDS, 1990, pp. 215-220, vol. 4.
Ishizaka, T., A. et al. “Molecular cloning of feline interferon-γ-inducing factor (interleukin-18) and its expression in various tissues,”Vet. Immunol. Immunopathol., 2001, pp. 209-218, vol. 79.
Johnson, C. M. et al. “FIV as a Model for AIDS Vaccination”AIDS Research and Human Retroviruses, 1994, vol. 10, No. 3, pp. 225-228.
Kakinuma, S. et al. “Nucleotide Sequence of Feline Immunodeficiency Virus: Classification of Japanese Isolates into Two Subtypes Which Are Distinct from Non-Japanese Subtypes”Journal of Virology, Jun. 1995, pp. 3639-3646, vol. 69, No. 6.
Karlin, S. et al. “Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes,”Proc. Natl. Acad. Sci. USA, 1990, pp. 2264-2268, vol. 87.
Karlin, S. et al. “Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences,”Proc. Natl. Acad. Sci. USA, 1993, pp. 5873-5877, vol. 90.
Lerner, D.L., et al. “Felis catus interleukin-4 mRNA,” NCBI GenBank, 1997 (accession U39634).
Leutenegger, C. M. et al. “Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif”Journal of Virology, Nov. 2000, pp. 10447-10457, vol. 74, No. 22.
Louwagie, J. et al. “Phylogenetic analysis ofgaggenes from 70 international HIV-1 isolates provides evidence for multiple genotypes”AIDS, 1993, pp. 769-780, vol. 7, No. 6.
Matsuo, K., et al., “Highly conserved epitope domain in major core protein p24 is structurally similar among human, simian and feline immunodeficiency viruses,”J. Gen. Virol., 1992, pp. 2445-2450, vol. 73.
McMichael, A.J., et al. “HIV vaccines 1983-2003,”Nat. Med., 2003. pp. 874-880, vol. 9.
Merrifield, R. B. “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide”Amer. Chem. Soc., Jul. 20, 1963, pp. 2149-2156, vol. 85.
Murphy, F. et al. “Virus Taxonomy”Fields Virology, 1990, pp. 9-36, Chapter 2, 2ndedition, Raven Press, Ltd., New York.
Murphy, F.A. “Virus Taxonomy,” In:Fundamental Virology, 3rd Ed., 1996, pp. 15-57, Fields BN, Knipe DM, PM Howley PM (editors). Lippincott, Raven Publishers, Philadelphia.
Nath, M.D., et al. “In vitro assembly of feline immunodeficiency virus capsid protein: biological role of conserved cysteines,”Arch. Biochem. Biophys., 2001, pp. 287-294, vol. 392.
Nixon, D.F., et al. “An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope,”AIDS, 1990, pp. 841-845, vol. 4.
Norrgren, H., et al. “Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection,”AIDS, 1999, pp. 701-707, vol. 13.
Okada, S. et al. “Superinfection of Cats with Feline Immunodeficiency Virus Subtypes A and B”AIDS Research and Human Retroviruses, 1994, vol. 10, No. 12, pp. 1739-1746.
Olmsted, R. et al. “Molecular clonin
Kinsey White Nicole
Mondesi Robert B
Saliwanchik Lloyd & Saliwanchik
University of Florida Research Foundation Inc.
LandOfFree
Materials and methods for immunizing against FIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for immunizing against FIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for immunizing against FIV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227238